Pancragen

Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator family, researched for pancreatic-tissue-targeted bioregulation, glucose regulation, and pancreatic beta-cell function. It is one of the better-studied Khavinson compounds in terms of mechanistic research, with chromatin-interaction studies providing relatively direct molecular evidence for the proposed epigenetic mechanism. Pancragen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Pancragen and how does the pancreatic bioregulatory mechanism work?

Pancragen is a synthetic Lys-Glu-Asp-Trp tetrapeptide proposed to enter pancreatic cell nuclei and modulate gene expression in pathways related to insulin production, pancreatic beta-cell function, and glucose homeostasis. It is among the Khavinson compounds with relatively well-characterized mechanistic studies — chromatin immunoprecipitation work has demonstrated tetrapeptide binding to specific DNA promoter regions in pancreatic-cell models. For the framework itself, see the science of Khavinson bioregulators. Within the Khavinson framework, Pancragen complements Ovagen (hepatic) in metabolic-organ targeting.

Evidence level: preclinical (cell culture with chromatin interaction data, rodent metabolic models); Khavinson-group research; independent replication limited

What does the research show for Pancragen?

Preclinical studies have reported effects on pancreatic gene expression markers, insulin secretion parameters in beta-cell culture models, and glucose tolerance improvements in diabetic rodent models. Chromatin immunoprecipitation studies from the Khavinson group have provided some of the most direct molecular evidence for the bioregulator framework, showing Pancragen binding to specific DNA promoter regions. Pancragen has been studied in experimental-diabetes and age-related glucose-tolerance models — rats with induced diabetes and aged rhesus monkeys with impaired glucose tolerance — plus a small Khavinson-group observational study in elderly people; it is not an approved or clinically established diabetes treatment. FDA-grade Phase 2/3 has not been conducted.

Sources: Effects of pancragen on the differentiation of pancreatic cells during their ageing, Khavinson V.Kh. et al., Bull Exp Biol Med, 2013; Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus, Khavinson V.Kh. et al., Bull Exp Biol Med, 2007; Prospects of using pancragen for correction of metabolic disorders in elderly people, Korkushko O.V. et al. (optional, non-blocking follow-up: confirm full list), Bull Exp Biol Med, 2011 · Evidence level: preclinical with mechanistic detail; Khavinson-group human research; FDA-grade Phase 2/3 not conducted

How does Pancragen compare to GLP-1-class diabetes compounds?

Pancragen operates through the proposed Khavinson epigenetic mechanism on pancreatic gene expression; GLP-1-class compounds like semaglutide and tirzepatide work through defined GLP-1 receptor pathways with extensive Phase 3 clinical evidence in type 2 diabetes. They are not mechanistically comparable, and the evidence base for diabetes efficacy is vastly larger for GLP-1 agonists.

What are the documented side effects of Pancragen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The favorable safety profile is consistent across the Khavinson bioregulator class. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Pancragen?

Pancragen is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Pancragen is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Pancragen vendor verification matter?

Pancragen's tetrapeptide structure (Lys-Glu-Asp-Trp) is shared in core composition with other Khavinson tetrapeptides — making mass spectrometry identity confirmation essential to verify the correct sequence and the tryptophan residue specifically. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Pancragen vendors?

Peptigrity collects independent third-party Certificates of Analysis for Pancragen from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Pancragen do?

Pancragen is proposed to act on pancreatic tissue through epigenetic gene-expression modulation, with preclinical research focused on insulin secretion, beta-cell function, and glucose tolerance. Some of the more direct mechanistic evidence for the bioregulator framework comes from chromatin-interaction studies of Pancragen.

Is Pancragen a diabetes treatment?

No. Pancragen is not approved for diabetes treatment anywhere in the world. FDA-approved diabetes peptides include semaglutide, tirzepatide, and other GLP-1-class compounds — all with substantially larger evidence bases than Pancragen. Anyone considering diabetes management should consult a licensed physician about evidence-based options.

Is Pancragen legal to purchase?

Pancragen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Pancragen be FDA-approved?

No active FDA approval pathway exists for Pancragen as of August 2026.

How can I verify a Pancragen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (the tryptophan residue is structurally distinctive and verifiable). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Pancragen dose?

No. Pancragen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Pancragen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.